Date: 2017-07-06
Type of information: Collaboration agreement
Compound:
Company: Eli Lilly (USA - IN) Purdue University (USA - IN)
Therapeutic area: CNS diseases
Type agreement: collaboration
Action mechanism:
Disease: pain
Details:
- • On July 6, 2017, Eli Lilly and Purdue University announced a strategic collaboration to conduct life science research. The initial research focus areas include:
- - Developing improved delivery of injectable medicines with the goals of reducing pain, decreasing the number of injections, and enabling better patient compliance and overall health.
- - Developing predictive models for clinical success that reduce risks associated with investing in drug development and more effectively predict the outcome of new therapies in humans.
- The collaboration envisions expansion to other areas to further utilize the range of expertise at the two institutions.
- Purdue researchers from the natural and physical sciences, engineering and veterinary medicine will contribute to the interdisciplinary collaboration with Lilly researchers.
Financial terms:
- The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company.
Latest news:
Is general: Yes
